Alexza Pharmaceuticals
Focused on multiple clinical stage therapeutics all leveraging the proprietary Staccato™ system for rapid delivery of drugs to the CNS to treat acute agitation, migraine, breakthrough pain, panic attacks, and insomnia

Alnara
Focused on developing non-systematic protein therapeutics for the treatment of metabolic diseases

Amicus Therapeutics
Developing clinical pipeline of oral small molecule chaperone therapeutics to treat lysosomal storage disease, including Fabry, Gaucher, and Pompe, as well as other genetic diseases

Anaptys
Developing novel anitbody therapeutics using proprietary somatic hypermutation platform

Arete Therapeutics
Clinical stage company developing a small molecule portfolio to soluble epoxide hydrolase to treat metabolic and cardiovascular disease

Array BioPharma
Developing a clinical pipeline of oral small molecule drugs to treat cancer and inflammatory diseases (Exited)

Cadence Pharmaceuticals
Clinical stage, hospital-focused company awaiting FDA approval of OFIRMEV™ for acute pain.

Calistoga Pharmaceuticals
Clinical stage company developing small molecule portfolio in the PI-3 kinase family to treat cancer and inflammation

Calixa Therapeutics
Clinical stage, infectious disease company in clinical trials with a potent antibiotic to treat gram negative infections, including those from the hard-to-treat Pseudomonas. Acquired by Cubist in December 2009. (Exited)

Cerexa
Acquired by Forest Labs (FRX). Now a wholly-owned subsidiary developing Ceftaroline™ and other novel anti-infectives for life threatening bacterial infections (Exited)

Chimerix
Clinical stage company with pipeline of anti-viral assets to treat smallpox, HPV, CMV, HIV leveraging proprietary platform technology to improve oral drug delivery

Collegium Pharmaceutical
Specialty pharmaceutical company focused on the development of proprietary, later stage pharmaceutical products in the pain, respiratory and dermatology fields

Cotherix
Developed Ventavis™ for pulmonary arterial hypertension (Exited)

CV Therapeutics
Developed Ranexa™ for chronic angina and clinical pipeline of small molecule therapeutics to treat cardiovascular disease (Exited)

Geron
Anti-cancer drugs and cancer vaccines targeting the enzyme telomerase as well as developing embryonic stem cell-based therapeutics (Exited)

Intradigm
Preclinical stage company developing proprietary platform of novel, systemically delivered RNAi therapeutics

Marcadia Biotech
Clinical stage company developing pipeline of peptide therapeutics to treat metabolic diseases

Nuon Therapeutics
Clinical stage company developing Tranilast® to treat rheumatoid arthritis and other indications

OraPharma
Developed Arrestin™ for periodontal diseases (Exited)

Portola Pharmaceuticals
Clinical stage company developing next-generation antithrombotic drugs, including oral Factor Xa inhibitor, Betrixaban™, and an ADP receptor antagonist, for acute and chronic cardiovascular disease

QuatRx
Clinical stage company in Phase III trials with Osphena™ for post-menopause vaginal atrophy

Rigel
Developing small molecule drugs for inflammatory/autoimmune diseases, cancer, viral and metabolic diseases (Exited)

Stromedix
Clinical stage company developing antibody to avb6 to treat fibrosis associated with renal transplantation

Tobira Therapeutics
Clinical stage HIV company developing best in class CCR5 therapeutics

Trubion Pharmaceuticals
Developing small modulatory immunoparticles (SMIPs) for CD20, CD37 and other high value targets

Tularik
Engaged in the discovey and development of a broad range of novel and superior oral available medicines that act through the regulation of gene expression. (Exited)

VentiRx Pharmaceuticals
Clinical stage company developing small molecule portfolio in the TLR family to treat cancer, infectious, repiratory and autoimmune diseases

ViroPharma
Developing novel therapies to treat infectious disease including its marketed product Vancocin™ for treatment of colitis from Clostridium difficile (Exited)

Vivus
Clinical portfolio to treat obesity and sexual health (Exited)

XenoPort
Clinical portfolio including Solzira™ for restless legs syndrome and neuropathic pain as well as pipeline of drugs to treat GERD, Parkinsons and migraine, all developed using its proprietary platform technology to improve bioavailability (Exited)

Zymogenetics
Focused on developing a pipeline of therapeutic proteins including Recothrom™ for hemostasis (Exited)

Ascension
Leading orthopedics company addressing unmet needs in the extremeties field

Barosence
Developing trans-oral medical devices and procedures for addressing obesity and its co-morbidities

BARRX Medical
Provides solutions for Barrett's esophagus, a precancerous change to the thin layer of tissue lining the esophagus

Calibra Medical
Developing a mechanical disposable insulin pump.

Calypso Medical
Developed and selling a system to guide precise targeting of radiation therapy

Cardiac Dimensions
Developing novel interventional tools for the treatment of mitral valve regurgitation

CVRX
Developing stimulation-based products to treat hypertension and other chronic conditions

EBR Systems
Pursuing novel approaches in cardiac rhythm management

FlowCardia
Focused on the treatment of chronic total occlusions in coronary artery and peripheral vascular disease (Exited)

Glaukos
Clinical stage ophthalmology company developing treatments for glaucoma

InnerPulse
Developing a disruptive interventional technology platform for cardiac rhythm management devices

PatientKeeper
Market leader in mobile HCIT solutions for healthcare providers

PowerVision
Developing an accommodating intraocular lens implant for the correction of Presbyopia

Primaeva
Early stage medical device company developing a skin tightening and rejuvenation dermatological device (Exited)

Xoft
Developing a family of micro-miniature x-ray source based medical devices to address various types of cancers

Zeltiq Aesthetics
Developing new technologies for non-invasive fat layer reduction

Zonare
A paradigm-shifting ultrasound company